Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial

The Lancet HIV 2026 Open access

Read full text
Authors: Elizabeth D. Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, Grace Kovic, Sanjna Merchant, Kaleb Branch, Chermiqua Rachelle Tsosie, Martina Zapata Vaca, Barbara Heckman, Rodica M Van Solingen-Ristea, Conn M. Harrington, Dwight E Yin
+28 more Ellen Townley, Michael Whitton, Allison L Agwu, Christiana Smith, Mary E Paul, Avy Violari, Evette Moodley, Maxensia Owor, Kulkanya Chokephaibulkit, Samantha Fry, Jennifer K. Jao, Charles D Mitchell, Sarah Buisson, Andi Ace, Irina Kolobova, Carolyn Bolton-Moore, Aditya H. Gaur, Annie Buchanan, Jenny O. Huang, Eileen Birmingham, Kati Vandermeulen, Sisinyana Ruth Mathiba, Pradthana Ounchanum, Gaerolwe R. Masheto, Linda Aurpibul, Violet Korutaro, Faeezah Patel, Andres Camacho-Gonzalez
DOI: 10.1016/s2352-3018(25)00241-3
Cited by: 1
References: 27

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV-related health complications and treatments HIV/AIDS Research and Interventions

Publication details

Journal / source
The Lancet HIV
Publisher
Elsevier BV
Volume
13
Issue
2
Pages
e95–e103
Publication date
15 January 2026
Language
EN